Cargando…
Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study
Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. A retrospective...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377952/ https://www.ncbi.nlm.nih.gov/pubmed/37510057 http://dx.doi.org/10.3390/diagnostics13142313 |
_version_ | 1785079645296656384 |
---|---|
author | Falvo, Nicolas Latreche, Amine Chevallier, Olivier Ledan, Frédérik Jandot, Maud Daoud, Héla Fréchier, Léo Loffroy, Romaric |
author_facet | Falvo, Nicolas Latreche, Amine Chevallier, Olivier Ledan, Frédérik Jandot, Maud Daoud, Héla Fréchier, Léo Loffroy, Romaric |
author_sort | Falvo, Nicolas |
collection | PubMed |
description | Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. A retrospective observational study of consecutive adults managed with endovenous cyanoacrylate was conducted in 2018–2021 at a single university center. The follow-up was 18 months. We identified factors associated with target vein closure at 18 months and measured changes in quality of life using the generic 36-item Short-Form (SF-36) tool and the venous disease-specific VEINES-QOL/Sym questionnaire. Adverse events were collected. In the 55 study patients with 67 treated veins, the closure rate at 18 months was 94% (95% CI, 85–98%). Target vein diameter ≥9.5 mm had 81% sensitivity and 75% specificity for predicting recanalization. Quality-of-life scores improved significantly (p < 0.001 for both surveys). The only adverse event was a type IV allergic reaction to cyanoacrylate that was resolved with corticosteroid and histamine-antagonist therapy. Endovenous cyanoacrylate ablation was highly effective and is safe in experienced hands. Studies are warranted to determine whether changes in the protocol increase the closure rate in patients with target veins ≥9.5 mm in diameter. |
format | Online Article Text |
id | pubmed-10377952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103779522023-07-29 Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study Falvo, Nicolas Latreche, Amine Chevallier, Olivier Ledan, Frédérik Jandot, Maud Daoud, Héla Fréchier, Léo Loffroy, Romaric Diagnostics (Basel) Article Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. A retrospective observational study of consecutive adults managed with endovenous cyanoacrylate was conducted in 2018–2021 at a single university center. The follow-up was 18 months. We identified factors associated with target vein closure at 18 months and measured changes in quality of life using the generic 36-item Short-Form (SF-36) tool and the venous disease-specific VEINES-QOL/Sym questionnaire. Adverse events were collected. In the 55 study patients with 67 treated veins, the closure rate at 18 months was 94% (95% CI, 85–98%). Target vein diameter ≥9.5 mm had 81% sensitivity and 75% specificity for predicting recanalization. Quality-of-life scores improved significantly (p < 0.001 for both surveys). The only adverse event was a type IV allergic reaction to cyanoacrylate that was resolved with corticosteroid and histamine-antagonist therapy. Endovenous cyanoacrylate ablation was highly effective and is safe in experienced hands. Studies are warranted to determine whether changes in the protocol increase the closure rate in patients with target veins ≥9.5 mm in diameter. MDPI 2023-07-08 /pmc/articles/PMC10377952/ /pubmed/37510057 http://dx.doi.org/10.3390/diagnostics13142313 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Falvo, Nicolas Latreche, Amine Chevallier, Olivier Ledan, Frédérik Jandot, Maud Daoud, Héla Fréchier, Léo Loffroy, Romaric Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study |
title | Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study |
title_full | Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study |
title_fullStr | Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study |
title_full_unstemmed | Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study |
title_short | Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study |
title_sort | cyanoacrylate glue for treating chronic saphenous vein insufficiency: a retrospective observational single-center study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377952/ https://www.ncbi.nlm.nih.gov/pubmed/37510057 http://dx.doi.org/10.3390/diagnostics13142313 |
work_keys_str_mv | AT falvonicolas cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy AT latrecheamine cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy AT chevallierolivier cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy AT ledanfrederik cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy AT jandotmaud cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy AT daoudhela cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy AT frechierleo cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy AT loffroyromaric cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy |